Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self‐Control

• Published in: Alcoholism, clinical and experimental research clinical and experimental research, 2017-07, Vol.41 (7), p.1370-1380
• Main Authors: Anton, Raymond F., Schacht, Joseph P., Voronin, Konstantin E., Randall, Patrick K.
• Format: Article
• Language: English
• Subjects: Adult; Alcohol; Alcohol Drinking - drug therapy; Alcohol Drinking - psychology; Alcohol use; Alcohol Use Disorder; Alcoholic beverages; Alcoholism - drug therapy; Alcoholism - psychology; Antipsychotic Agents - pharmacology; Antipsychotic Agents - therapeutic use; Aripiprazole; Aripiprazole - pharmacology; Aripiprazole - therapeutic use; Breath tests; Cortex; Dependence; Dopamine; Drinking; Drinking behavior; Drug dependence; Female; Humans; Impulsive Behavior; Impulsivity; Laboratories; Latency; Male; Pharmacotherapy; Reinforcement; Self control; Serotonin; Side effects; Young Adult
• ISSN: 0145-6008; 1530-0277
• DOI: 10.1111/acer.13417

Background Aspects of impulsivity have been implicated in the development, or maintenance, of alcohol use disorder (AUD). The brain dopamine system is implicated in both reward processing/memory (typically subcortical) and in brain inhibitory control mechanisms (typically cortical). Using a validated clinical laboratory paradigm, the dopamine/serotonin “stabilizing” drug, aripiprazole was evaluated in non‐treatment‐seeking AUD individuals based on their level of impulsivity/self‐control. Methods Ninety‐nine individuals (77% male; mean age 27; 7.5 drinks per day; 83% heavy drinking days) meeting DSM‐IV criteria for alcohol dependence were randomized to aripiprazole (N = 47 evaluable) or placebo (N = 48 evaluable) based on their Barratt Impulsiveness Scale (BIS‐11) score (above or below 68). Aripiprazole, or similar placebo, was titrated to 15 mg over 8 days. Drinking was recorded over 6 days under natural conditions. On Day 8, after 1 day of required abstinence, individuals participated in a bar laboratory paradigm that included a priming drink (breath alcohol concentration [BAC] target 0.02 to 0.03 g/dl) and free‐choice consumption of up to 8 drinks (max BAC 0.1 g/dl) in exchange for a “bar credit” of $2 per drink (max $16). End points were drinks per day under natural conditions and drinks consumed in the bar laboratory after the priming drink. Results There was no significant main effect of aripiprazole or interaction with BIS‐11 score during the natural drinking period. However, there was a main effect of aripiprazole on bar laboratory drinking (p = 0.04) and aripiprazole reduced the total number of drinks consumed more among individuals with low self‐control (p = 0.034) and increased latency to consume those drinks (p = 0.045) more among those with high impulsivity. Relative to placebo, aripiprazole caused more side effects and increased alcohol‐induced sedation, but neither significantly influenced its interaction with impulsivity/self‐control scores on drinking. Conclusions This paradigm forced a choice between immediate drinking reward and delayed monetary reward. In those with high impulsivity and/or low self‐control, aripiprazole shifts the balance away from immediate drinking toward a later reward. Medications targeting cortical dopamine/serotonin balance might show clinical benefit of reduced drinking, among individuals with impulsivity/low self‐control. This study showed that the dopamine‐stabilizing medication aripiprazole, compared to placebo